US2020214995A1PendingUtilityA1

Treatment of autism with cannabidiol

72
Assignee: ZYNERBA PHARMACEUTICALS INCPriority: Sep 28, 2017Filed: Jan 8, 2020Published: Jul 9, 2020
Est. expirySep 28, 2037(~11.2 yrs left)· nominal 20-yr term from priority
Inventors:Terri SebreeMarcel Bonn-MillerDonna Gutterman
A61K 36/3482A61K 31/658A61P 25/22A61K 9/0014A61P 25/18A61K 9/06A61P 25/00A61K 36/185A61K 31/05
72
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

Claims

exact text as granted — not AI-modified
1 - 30 . (canceled) 
     
     
         31 . A method of treating a human suffering from an autism spectrum disorder comprising:
 transdermally administering via a gel or cream a therapeutically effective amount of purified cannabidiol to the human suffering from the autism spectrum disorder to effectively treat the autism spectrum disorder in the human in need thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.